title: Randomized, double-blind study of the clinical efficacy of 3 days of azithromycin compared with co-amoxiclav for the treatment of acute otitis media.
abstract: BACKGROUND
  Compared with 5 days of dosing, a 3 day dosing regimen of azithromycin for treatment of acute otitis media (AOM) may improve compliance, will simplify therapy for the caregiver and, by giving the same total dose as the 5 day regimen, provide more drug when the bacterial burden is highest.
  
  
  METHODS
  Children of 6 months-12 years were enrolled if they had had symptoms and signs of AOM for <4 weeks and tympanic membrane effusion by acoustic reflectometry. Eligible children were randomized to azithromycin 10 mg/kg/day x 3 days or co-amoxiclav 45 mg/kg/day x 10 days. The primary endpoint was clinical response at day 28.
  
  
  RESULTS
  One hundred and eighty-eight children (mean age 3.5 years) were randomized to azithromycin and 185 to co-amoxiclav. At day 10, the clinical success rate was 153/185 (83%) in children treated with azithromycin and 159/181 (88%) in children treated with co-amoxiclav. At day 28, 134/182 (74%) of the children were cured on azithromycin compared with 124/180 (69%) on co-amoxiclav. Also at day 28, signs of AOM, such as abnormal reflectometry (45% versus 59%; P = 0.017), bulging of the eardrum (10% versus 16%; P = 0.059) and loss of tympanic membrane landmarks (11% versus 22%; P = 0.010) were seen less frequently in azithromycin- than co-amoxiclav-treated children, respectively. Adverse events related to therapy were seen in 11% of azithromycin patients compared with 20% on co-amoxiclav (P = 0.014).
  
  
  CONCLUSIONS
  Azithromycin given over 3 days is as effective as co-amoxiclav for treatment of AOM, may result in more complete resolution of tympanic membrane disease, and is better tolerated.
authors.affiliation: Pfizer Global Research & Development, 50 Pequot Ave. MS 6025-C2173, New London, CT 06320, USA. michael_w_dunne@groton.pfizer.com
authors.forename: Michael W
authors.initials: MW
authors.lastname: Dunne
authors.forename: Thomas
authors.initials: T
authors.lastname: Latiolais
authors.forename: Barnett
authors.initials: B
authors.lastname: Lewis
authors.forename: Bruce
authors.initials: B
authors.lastname: Pistorius
authors.forename: Gerald
authors.initials: G
authors.lastname: Bottenfield
authors.forename: William H
authors.initials: WH
authors.lastname: Moore
authors.forename: Anne
authors.initials: A
authors.lastname: Garrett
authors.forename: Tracy D
authors.initials: TD
authors.lastname: Stewart
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Aoki
authors.forename: Craig
authors.initials: C
authors.lastname: Spiegel
authors.forename: David
authors.initials: D
authors.lastname: Boettger
authors.forename: Anne
authors.initials: A
authors.lastname: Shemer
mesh_terms: D000208:Acute Disease; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000009:adverse effects / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017963:Azithromycin / Q000009:adverse effects / Q000627:therapeutic use*; D002675:Child, Preschool; D004311:Double-Blind Method; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006320:Hearing Tests; D006801:Humans; D007223:Infant; D008297:Male; D010033:Otitis Media / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome; D014432:Tympanic Membrane / Q000473:pathology
chemical_list: D000900:Anti-Bacterial Agents; D019980:Amoxicillin-Potassium Clavulanate Combination; D017963:Azithromycin